Document:

Executive Employment Agreement between Dendreon Corp & Grant E. Pickering

 Exhibit 10.4 
  
 DENDREON CORPORATION 
  
 EXECUTIVE EMPLOYMENT AGREEMENT 
  
 (WASHINGTON STATE) 
  
 This Executive Employment Agreement (“Agreement”) is entered into as of the date of the last signature to this Agreement
(“Effective Date”), by and between Dendreon Corporation, a Delaware corporation (the “Company”), and Grant E. Pickering (“Employee”). 
  
 The parties agree as follows: 
  
 1. Employment. The Company hereby employs Employee as Senior
Vice President, Operations, and Employee hereby accepts such employment, upon the terms and conditions set forth in this Agreement. 
  
 2. Duties. 
  
 2.1 Position. Employee shall perform such duties as are customary for the position of Senior Vice President, Operations, and any additional
duties that the President and Chief Executive Officer may reasonably prescribe from time to time. Employee shall devote Employee’s full business time and efforts to the performance of Employee’s assigned duties for the Company,
provided, however, that Employee may devote reasonable periods of time to (a) serving on the board of directors of other corporations subject to the prior approval of the President and Chief Executive Officer, and (b) engaging in
charitable or community service activities, so long as none of the foregoing additional activities interfere with Employee’s duties under this Agreement. 
  

2.2 Work Location. Employee’s principal place of work shall be located in Seattle, Washington, or such other location as the parties
may agree upon from time to time. 
  
 3.
Term. The employment relationship pursuant to this Agreement shall begin on the Effective Date, will be for no specified term, and may be terminated by Employee or the Company at any time, with or without Cause (as defined in Section
6), subject to the provisions regarding termination set forth in Section 6. 
  
 4. Compensation. 
  
 4.1 Base Salary. As compensation for Employee’s performance of his duties under this Agreement, the Company shall pay Employee a base salary (“Base Salary”), which shall initially equal Two Hundred
Fifty-Two Thousand Dollars ($252,000) per year, payable in accordance with the normal payroll practices of the Company, less required deductions for state and federal withholding tax, social security and all other required employment taxes and
payroll deductions. The Base Salary may not be reduced for reasons unrelated to Employee’s performance unless the base salaries of all other employees of the Company at the Vice President level and above are proportionally reduced. 

 

 1 

 4.2 Incentive Compensation. Within thirty (30) days after the end of each calendar year, if
the Company and Employee meet specified targets agreed upon in advance by the Board, Employee shall be entitled to receive a bonus of up to forty percent (40%) of his Base Salary (the “Annual Bonus”) as determined by the
Board or its designee, in its sole discretion. If the Company and Employee do not fully meet such targets, the Company may pay Employee a bonus of such amount as the Board or its designee deems appropriate in its sole discretion. Before the
beginning of a new bonus year, the Board may, in its discretion, reduce the percentage of the Annual Bonus applicable to employees, provided that Employee’s Annual Bonus may be reduced only to the extent that the percentage annual bonuses of
all other employees of the Company at the Vice President level and above are proportionally reduced. 
  
 4.3 Performance and Compensation Review. The Employee’s performance will be reviewed on no less than an annual basis to determine
whether Employee’s salary or other compensation should be modified. 
  
 4.4 Vacation. Employee shall be eligible to earn four (4) calendar weeks of paid vacation in each year of this Agreement. Vacation will accrue at the rate of thirteen and one-third (13  1/3rd) hours per month, and may be carried over from year to year up to a maximum cap of 240 hours. Any accrued unused
vacation will be cashed out upon termination of employment at Employee’s then current Base Salary rate. 
  
 4.5 Benefits and Insurance. In addition to the vacation benefits in Section 4.4 above, Employee shall be entitled to all benefits that the
Company may make generally available from time to time to its employees, subject to the terms and conditions of the applicable policy or plan, and provided that Employee understands that he/she will be designated as a key employee for purposes of
any FMLA leave. 
  
 5. Business Expenses. The
Company shall pay, or promptly reimburse, Employee for all reasonable, out-of-pocket travel and business expenses incurred in the performance of Employee’s duties on behalf of Company for which Employee submits the required supporting
documentation and otherwise fully complies with the Company’s travel and expense reimbursement policy as in effect from time to time. 
  
 6. Separation of Employee’s Employment. 
  
 6.1 Termination for Cause by Company. The Company may terminate Employee’s employment at any time for
Cause. For purposes of this Agreement, “Cause” is defined as: Employee’s continued neglect or failure to perform his duties and responsibilities satisfactorily, after written notice thereof; willful misconduct by
Employee with respect to his duties and responsibilities under this Agreement; conduct which is materially injurious (monetarily or otherwise) to the Company, including without limitation, misuse of Company funds or property; unethical business
practices or dishonesty related to the Company’s business; any other material breach by Employee of this Agreement or any noncompetition, nondisclosure and/or invention agreement with the Company; conviction of a felony or misdemeanor involving
moral turpitude; or any similar or related act or failure to act by Employee which is materially adversely injurious to the Company. In the event that Employee’s employment is terminated in accordance with this Section 6.1, Employee shall be
entitled to receive, on Employee’s first regular payday following his Termination Date, a lump sum payment equal to the following: (i) Employee’s then current Base Salary, prorated to the date of termination of employment
(“Termination Date”), and (ii) any accrued unused vacation as of the Termination Date, all of the foregoing to be less required withholding. All other Company 
  

 2 

 obligations to Employee, including but not limited to any bonus as described in Section 4.2 and Severance (as defined in
Section 6.2), and excepting the Company’s obligations in Section 8.8 (Dispute Resolution) will automatically terminate and be completely extinguished as of the Termination Date. 
  
 6.2 Termination Without Cause. If the Company terminates Employee’s employment without Cause, or if
Employee resigns for Good Reason in accordance with Section 6.3, Employee will be entitled to receive, on Employee’s first regular payday following his Termination Date, the following: (a) a lump sum severance payment in an amount equal to
three-fourths (3/4ths) of Employee’s then current Base Salary, (b) three-fourths (3/4ths) of the amount of maximum Annual Bonus payable to Employee for the then calendar year, (c) all accrued, unused vacation, all (a), (b), and (c) to be less
required withholding; (d) payment of reasonable costs not to exceed $10,000 for outplacement services provided by a purveyor approved by Company, upon delivery to the Company of an itemized invoice for such services; (e) payment by the Company for
continuation of all Health Benefits in effect on the Termination Date and timely elected by Employee under COBRA, for a period of eighteen (18) months following the Termination Date, or until Employee is eligible to receive comparable health
benefits from another Employer; and (f) full accelerated vesting of any and all unvested stock options and restricted stock grants held by Employee (together, “Severance”). All other Company obligations to Employee pursuant
to this Agreement, except those in Section 8.8 (Dispute Resolution), will automatically terminate and be completely extinguished as of the Termination Date. 
  
 6.3 Resignation of Employee for Good Reason. Employee will be deemed to have resigned for “Good Reason” if any of
the following events or conditions occur without the Employee’s express consent: 
  

	 	(a)	The Board or Company (i) alters Employee’s duties, responsibilities or title resulting in a significant diminution of the Employee’s position, duties, responsibilities or
status with the Company and (ii) contemporaneously reduces Employee’s Base Salary, unless the base salaries of all other employees of the Company at the Vice President level or above are proportionately reduced; or 

  

	 	(b)	The Board or Company transfers or assigns Employee to any location that is more than fifty (50) miles from the location of Employee’s principal office. Required travel on the
Company’s business that is consistent with the business travel obligations of Employee’s position is excluded from this Section. 

  
 6.4 Resignation by Employee Without Good Reason. Employee may voluntarily resign his position with the Company without Good Reason at any
time on thirty (30) days’ advance written notice. In the event Employee’s resignation is without Good Reason, Employee will be entitled to receive, on Employee’s first regular payday following his Termination Date, a lump sum payment
equivalent to the following: (i) the Base Salary then in effect, prorated to the Termination Date; and (ii) accrued unused vacation as of the Termination Date, all of the foregoing to be less required withholding. All other Company obligations to
Employee pursuant to this Agreement, except those in Section 8.8 (Dispute Resolution), will automatically terminate and be completely extinguished. 
  

 3 

 6.5 Employee’s Execution of Release. The payment of Severance pursuant to Section 6.2,
6.3, or Section 6.6(b) is expressly contingent upon execution by Employee or his duly authorized representative of a full and general release of any and all claims against the Company and its officers and directors in the form reasonably required by
the Company. 
  
 6.6 Termination Upon Death or
Disability. 
  
 (a) Death.
Employee’s employment will terminate automatically upon death of the Employee. In the event of Employee’s death, Employee’s Base Salary then in effect, prorated to the Termination Date, and any accrued unused vacation as of the
Termination Date, all of the foregoing to be less required withholding, shall be paid, on the Employee’s first regular payday following his Termination Date, to the beneficiary designated in writing by the Employee (“Beneficiary”) or,
if no such Beneficiary is designated, to the Employee’s estate. In addition, (i) the Company will continue the Employee’s Base Salary until the earlier of six months from the Termination Date or the commencement of death benefits under any
existing Company Group Life Insurance Plan, and (ii) the Company shall fully accelerate vesting of any and all unvested stock options and restricted stock grants held by Employee. 
  
 (b) Disability. In the event that Employee becomes physically or mentally disabled such that he/she is unable
to perform his duties for a period of three (3) consecutive months as determined by a medical professional (“Disability”), the Company may terminate Employee’s employment, unless otherwise prohibited by law. In the event
of termination due to Disability, Employee shall be paid, on the Employee’s first regular payday following his Termination Date, a lump sum payment equivalent to Employee’s Base Salary then in effect prorated to Employee’s Termination
Date, and any accrued unused vacation as of the Termination Date, all of the foregoing to be less required withholding. In addition, (i) the Company will continue Employee’s Base Salary (less any short term disability payments Employee receives
from the Company) until the earlier of six (6) months from the Termination Date or the commencement of Long Term disability payments under any existing Company Long Term Disability Policy; and (ii) the Company shall fully accelerate vesting of any
and all unvested stock options and restricted stock grants held by Employee. 
  
 6.7 Board Action. The Company agrees to take all actions required by the Board or otherwise to accelerate Employee’s unvested stock options and restricted stock grants as required by Sections 6.2,
6.3, or 6.6. 
  
 6.8 Change in Control. In the event
of the Employee’s “Involuntary Termination Without Cause” or “Termination For Good Reason” as defined in the Dendreon Corporation Change of Control Executive Severance Plan (“Change of Control Severance Plan”),
during the “Severance Period” as defined in the Change of Control Severance Plan, the terms of the Change in Control Severance Plan shall govern instead of this Agreement, provided, however, that if Employee’s employment is terminated
during the Severance Period due to a Disability as defined under this Agreement, this Agreement shall govern. In all other circumstances, this Agreement shall govern the Employee’s termination of employment. 
  

 4 

 7. Agreement Not to Compete. 
  
 7.1 No Employment with, or Connection to, Competitor. Employee agrees that, during the term of his employment
with the Company and for a period of nine (9) months thereafter, Employee will not, without securing the prior written permission of the Company: 
  
 (a) be employed by, act as an agent for, or consult with or otherwise perform services for, a Competitor (as defined below); or 
  
 (b) own any equity interest in, manage or participate in the management (as
an officer, director, partner, member or otherwise) of, or be connected in any other manner with, a Competitor, except that this section shall not restrict Employee from owning less than one percent (1%) of the equity interests of any publicly held
entity. 
  
 7.2 Nonsolicitation of Company Employees,
Customers, etc. Employee agrees that for a period of one (1) year following Employee’s Termination Date, Employee will not, without securing the prior written permission of the Company: 
  
 (a) induce or attempt to induce any Employee, officer, director, agent,
independent contractor, consultant, customer, strategic partner, licensor, licensee, supplier or other service provider of the Company to terminate a relationship with, cease providing services or products to, or purchasing products or services
from, the Company; or 
  
 (b) perform services or solicit the
opportunity to perform services for a customer or client of the Company for which or with which the Company was, as of Employee’s Termination Date, performing services, contracting for the performance of services or engaging in negotiations
with respect to a contract for the performance of services. 
  
 7.3 Definition of Competitor. The term “Competitor” as used in this Agreement means any individual or entity that is directly or indirectly engaged in the development and/or commercialization in the
United States of one or more ex vivo cellular immunotherapies for the therapeutic treatment of cancer, which ex vivo cellular immunotherapies generate twenty percent (20%) or more of either the annual gross revenue or worldwide operating expense of
such Competitor in the United States. The term “Competitor” also includes an individual or entity that is preparing to directly or indirectly engage in the development and/or commercialization in the United States of ex vivo
cellular immunotherapies, if such ex vivo immunotherapies are anticipated to generate twenty (20%) or more of either the annual gross revenue or annual operating expense of such Competitor in the United States during the first calendar year of
development and/or commercialization. 
  
 7.4 Reasonableness
of Restrictions. The Company and Employee agree that, in light of all of the facts and circumstances relating to the relationship that exists and is expected to exist between the Company and Employee, these restrictions (including, but not
limited to, the scope of the restricted activities, the duration of the restrictions, and the geographic extent of the restrictions) are fair and reasonably necessary for the protection of the goodwill and other protectable interests of the Company.
If a court or arbitrator of competent jurisdiction declines to enforce any of these restrictions, the Company and Employee agree that the restrictions shall be enforceable to the maximum extent allowed by law. 
  

 5 

 8. General Provisions. 
  
 8.1 Successors and Assigns. The rights and obligations of
Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company. Employee shall not be entitled to assign any of Employee’s rights or obligations under this Agreement. 

 
 8.2 Waiver. Either party’s failure to enforce any
provision of this Agreement shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Agreement. 
  
 8.3 Severability. In the event any provision of this Agreement
is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall
receive the benefits contemplated in this Agreement to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the
validity and enforceability of the remaining provisions shall not be affected. 
  
 8.4 Interpretation; Construction. The headings set forth in this Agreement are for convenience only and shall not be used in interpreting this Agreement. Both parties have participated in the negotiation
of this Agreement. Therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. 
  
 8.5 Notices. Any notice required or permitted by this Agreement
shall be in writing and shall be delivered as follows with notice deemed given as indicated: (a) by personal delivery when delivered personally; (b) by overnight courier upon written verification of receipt; (c) by telecopy or facsimile transmission
upon acknowledgment of receipt of electronic transmission; or (d) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth below, or such other address as either party
may specify in writing. 
  
 8.6 Survival. Section 6
(“Separation of Employee’s Employment”), Section 7 (“Agreement Not to Compete”), Section 8 (“General Provisions”) of this Agreement shall survive Employee’s employment by the Company. 
  
 8.7 Entire Agreement. This Agreement, the Company’s stock
option plan and documents reflecting options and restricted stock granted to Employee, the Proprietary Information and Inventions Agreement entered into by Employee at the commencement of his employment with the Company, and the Indemnity Agreement
entered into by the Company and Employee, if any, together with the Dendreon Corporation Change of Control Executive Severance Plan, constitute the entire agreement between the parties relating to this subject matter and supersede all prior or
simultaneous representations, discussions, negotiations, and agreements, whether written or oral. This Agreement may be amended or modified only with the written consent of Employee and a duly authorized officer of the Company. No oral waiver,
amendment or modification will be effective under any circumstances whatsoever. 
  
 8.8 Dispute Resolution. The parties agree that any dispute arising out of this Agreement shall be resolved by the parties through confidential mediation or final and binding confidential arbitration. The
parties will first attempt to mediate the dispute before a 
  

 6 

 neutral mediator agreed upon by the parties. If mediation is not successful, the dispute will be submitted to final and
binding confidential arbitration before a neutral arbitrator agreed upon by the parties. Except as specifically provided herein, the mediation or arbitration shall be governed by the rules of the American Arbitration Association or such other rules
as agreed to by the parties. Each party shall be responsible for their own costs and attorneys’ fees relating to mediation and arbitration. Both parties agree that the procedures outlined in this paragraph are the exclusive methods of dispute
resolution. 
  
 8.9 Injunctive Relief.
Notwithstanding the foregoing, any action brought by the Company under this Agreement seeking a temporary restraining order, temporary and/or permanent injunction and/or decree of specific performance of the terms of this Agreement may be brought in
a court of competent jurisdiction without the obligation to proceed first to mediation or arbitration. The Company shall not be required to post a bond as a condition for the granting of such relief. 
  
 8.10 Governing Law and Venue. This Agreement shall be governed
by, and construed in accordance with, the laws of the State of Washington as though made and to be fully performed in that State. Venue for any action, including mediation or arbitration under Section 8.8, arising from this Agreement shall be
exclusively in King County, Washington. 
  
 THE PARTIES TO THIS AGREEMENT HAVE
READ THIS AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION. 
  

					
	 	 	GRANT E. PICKERING
		
	 Dated: 10/7/2004
	 	 /s/ Grant E. Pickering

		
	 	 	Address:
		
	 	 	

		
	 	 	

		
	 	 	DENDREON CORPORATION
			
	 Dated: 10/8/2004
	 	By:	 	 /s/ Mitchell H. Gold, M.D.

			
	 	 	Its:	 	 President and Chief Executive Officer

  

 7Common Stock Purchase Agreement

 Exhibit 10.1 
  
 COMMON STOCK PURCHASE AGREEMENT 
  
 BY AND AMONG 
  
 PRICESMART, INC. 
  
 and 
  
 THE INVESTORS LISTED ON 
 EXHIBIT A ATTACHED HERETO 
  
 Dated as of October 4, 2004 

 TABLE OF CONTENTS 
  

							
	 1.
	 	 AGREEMENT TO PURCHASE AND SELL STOCK
	  	1
	 	 	 1.1
	  	Quantity and Price	  	1
	 	 	 1.2
	  	Waiver of Certain Rights	  	2
			
	 2.
	 	 CLOSING
	  	3
			
	 3.
	 	 REPRESENTATIONS AND WARRANTIES OF THE COMPANY
	  	3
	 	 	 3.1
	  	Organization, Good Standing and Qualification	  	3
	 	 	 3.2
	  	Authorization	  	3
	 	 	 3.3
	  	Valid Issuance of the Shares	  	4
	 	 	 3.4
	  	Capitalization	  	4
	 	 	 3.5
	  	Noncontravention	  	5
	 	 	 3.6
	  	Absence of Certain Changes	  	5
	 	 	 3.7
	  	No General Solicitation	  	6
	 	 	 3.8
	  	Disclosure	  	6
			
	 4.
	 	 REPRESENTATIONS AND WARRANTIES OF THE INVESTORS
	  	6
	 	 	 4.1
	  	Organization and Qualification	  	6
	 	 	 4.2
	  	Authorization	  	6
	 	 	 4.3
	  	Purchase for Own Account	  	6
	 	 	 4.4
	  	Accredited Investor Status	  	7
	 	 	 4.5
	  	Restricted Securities	  	7
	 	 	 4.6
	  	Due Diligence and No Solicitation	  	7
	 	 	 4.7
	  	Further Limitations on Disposition	  	7
	 	 	 4.8
	  	Legends	  	8
			
	 5.
	 	 PRE-CLOSING COVENANTS OF THE PARTIES
	  	8
	 	 	 5.1
	  	General	  	8
	 	 	 5.2
	  	Notice of Developments	  	8
	 	 	 5.3
	  	Transfer of Series B Preferred Stock	  	8
			
	 6.
	 	 POST-CLOSING COVENANTS OF THE PARTIES.
	  	9
	 	 	 6.1
	  	Listing	  	9
			
	 7.
	 	 CONDITIONS TO THE INVESTORS’ OBLIGATIONS AT CLOSING
	  	9
	 	 	 7.1
	  	Representations and Warranties True	  	9
	 	 	 7.2
	  	Compliance with Covenants	  	9
	 	 	 7.3
	  	No Litigation	  	9
	 	 	 7.4
	  	Securities Exemptions	  	10
	 	 	 7.5
	  	Proceedings	  	10
	 	 	 7.6
	  	No Material Adverse Effect	  	10
			
	 8.
	 	 CONDITIONS TO THE COMPANY’S OBLIGATIONS AT CLOSING
	  	10
	 	 	 8.1
	  	Representations and Warranties True	  	10
	 	 	 8.2
	  	Evidence of Cancellation	  	10
	 	 	 8.3
	  	No Litigation	  	11

  

							
	 	 	 8.4
	  	Securities Exemptions	  	11
	 	 	 8.5
	  	Stockholder Approval	  	11
	 	 	 8.6
	  	Termination of Security Interest	  	11
			
	 9.
	 	REGISTRATION STATEMENT FOR RESALE OF THE SHARES	  	11
	 	 	 9.1
	  	Registration	  	11
	 	 	 9.2
	  	Company Obligations	  	11
	 	 	 9.3
	  	Restrictions on Registrations	  	13
	 	 	 9.4
	  	Investor Obligations and Rights.	  	13
	 	 	 9.5
	  	Indemnification.	  	14
	 	 	 9.6
	  	Expenses	  	17
			
	 10.
	 	 TERMINATION
	  	17
	 	 	 10.1
	  	Termination	  	17
	 	 	 10.2
	  	Effect of Termination	  	17
			
	 11.
	 	 MISCELLANEOUS.
	  	18
	 	 	 11.1
	  	Survival of Warranties	  	18
	 	 	 11.2
	  	Specific Performance	  	18
	 	 	 11.3
	  	Successors and Assigns	  	18
	 	 	 11.4
	  	Governing Law	  	18
	 	 	 11.5
	  	Counterparts	  	19
	 	 	 11.6
	  	Headings	  	19
	 	 	 11.7
	  	Notices	  	19
	 	 	 11.8
	  	No Finder’s Fees	  	20
	 	 	 11.9
	  	Amendments and Waivers	  	20
	 	 	 11.10
	  	Attorneys’ Fees	  	20
	 	 	 11.11
	  	Severability	  	20
	 	 	 11.12
	  	Entire Agreement	  	20
	 	 	 11.13
	  	No Third Party Beneficiaries	  	20
	 	 	 11.14
	  	Public Announcements	  	20
	 	 	 11.15
	  	Further Assurances	  	20
	 	 	 11.16
	  	Fees and Expenses	  	21
	 	 	 11.17
	  	Waiver of Jury Trial	  	21

  
 SCHEDULES 
  
 Schedule 3.4(b) 
  
 EXHIBITS 
  

			
	Exhibit A	 	Schedule of Investors

 COMMON STOCK PURCHASE AGREEMENT 
  
 This COMMON STOCK PURCHASE AGREEMENT (including any Exhibits and Schedules hereto, this “Agreement“) is
made and entered into as of October 4, 2004 by and among PriceSmart, Inc., a Delaware corporation (the “Company“), and the investors listed on Exhibit A attached hereto (each an “Investor” and, collectively,
the “Investors“). The Investors and the Company are referred to herein individually as a “Party“ and together as the “Parties.” 
  
 WITNESSETH: 
  
 WHEREAS, the Company desires to sell to the Investors, and the Investors
desire to purchase from the Company, an aggregate of up to 7,976,526 shares (the “Shares”) of the Company’s common stock, par value $.0001 per share (“Common Stock“), on the terms and conditions set forth in
this Agreement. 
  
 NOW, THEREFORE, in consideration of the
premises and the mutual promises contained herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows: 
  
 1. AGREEMENT TO PURCHASE AND SELL STOCK. 
  
 1.1 Quantity and Price. Subject to the terms and conditions of this Agreement, the Company agrees to sell to each of
the Investors at the Closing (as defined below), and each of the Investors severally agrees to purchase from the Company at the Closing, that number of Shares set forth with respect to such Investor below for the consideration below: 
  
 1.1.1 Private Placement. On the Closing Date, the Company will issue
to The Price Group, LLC, a California limited liability company (the “Price Group”), a number of shares of Common Stock equal to the entire principal amount of that certain bridge loan extended to the Company by the Price Group on
August 31, 2004 (the “Bridge Loan”), together with all accrued and unpaid interest thereon, divided by $8. The purchase price per share shall be $8, payable by cancellation of the principal amount outstanding on the Bridge Loan,
together with accrued and unpaid interest thereon. At the Closing, the Price Group will deliver to the Company for cancellation the promissory note issued by the Company pursuant to the Bridge Loan. 
  
 1.1.2 Series B Exchange. On the Closing Date, the Company will
exchange an aggregate of 2,200,000 shares of Common Stock for all outstanding shares of the Company’s 8% Series B Cumulative Convertible Redeemable Preferred Stock, par value $.0001 per share (the “Series B Preferred Stock”).
The following Investors will exchange the number of shares of Series B Preferred Stock held by them at the time of the exchange for the number of shares of Common Stock set forth below: 
  
 (a) The Sol and Helen Price Trust will exchange 7,000 shares of Series B Preferred Stock for 700,000 shares of Common
Stock; 
  
 (b) The Price Family Charitable Fund will exchange
5,000 shares of Series B Preferred Stock for 500,000 shares of Common Stock; 

 (c) The Price Group will exchange 5,000 shares of Series B Preferred Stock for 500,000 shares of Common
Stock; 
  
 (d) The Robert and Allison Price Charitable Remainder
Trust will exchange 3,000 shares of Series B Preferred Stock for 300,000 shares of Common Stock; and 
  
 (e) The Robert and Allison Price Trust 1/10/75 will exchange 2,000 shares of Series B Preferred Stock for 200,000 shares of Common Stock. 
  
 At the Closing, each of the Investors holding Series B Preferred Stock shall tender to the
Company the certificates representing such shares endorsed for transfer or together with stock powers in blank. 
  
 1.1.3 Current Obligation Exchange. On the Closing Date, the Company will issue to the Price Group a number of shares of Common Stock equal to the
amount outstanding under that certain Purchase Order Financing Arrangement, dated February 23, 2004, by and between the Price Group and the Company, including any amendments thereto (the “Vendor Financing Agreement”), including
accrued and unpaid interest thereon, divided by $8. The purchase price per share shall be $8 and shall be payable by cancellation of the Company’s obligations to the Price Group under the Vendor Financing Agreement. On the Closing Date, the
Company and the Price Group will terminate that certain Agreement of Purchase and Sale (with Escrow Instructions) and Leaseback, dated May 6, 2004, by and between the Price Group and the Company as agent for and on behalf of its wholly-owned
(through a subsidiary company) subsidiary Inmobiliaria PriceSmart, S.A., a Dominican Republic company, including any amendments thereto (the “Deposit Agreement”). As a result of such termination, the Company will be obligated to
refund to the Price Group the deposit previously made thereunder by the Price Group, together with accrued and unpaid interest thereon. In full satisfaction of such obligation, the Company will issue to the Price Group a number of shares of Common
Stock equal to the amount outstanding under the Deposit Agreement, including accrued and unpaid interest thereon, divided by $8. The purchase price per share shall be $8 and shall be payable by cancellation of the Company’s obligations to the
Price Group under the Deposit Agreement. At the Closing, the Price Group will deliver to the Company such evidence or documentation as reasonably requested by the Company evidencing termination of all obligations of the Company under the Vendor
Financing Agreement and the Deposit Agreement, including any liens, security interests, pledges or encumbrances of any kind created under such agreements. 
  
 1.2 Waiver of Certain Rights. The Price Group, the Sol and Helen Price Trust and the Robert and Allison Price Trust 1/10/75 agree that they will
not exercise and will not convey to any other person or entity any rights granted to them pursuant to the Rights Offering (as defined in that certain Stockholder Voting Agreement, dated as of even date herewith, by and between the Company and the
Stockholders (as defined therein) (the “Voting Agreement”)), on shares of Common Stock issued to the them pursuant to this Section 1. The Sol and Helen Price Trust agrees that it will not exercise (and will not convey) any rights it
may received on shares of Common Stock issued to it pursuant to the Series A Exchange (as defined in the Voting Agreement). 
  

 2 

 2. CLOSING. The purchase and sale of the Shares (the “Closing“)
will take place at the offices of PriceSmart, Inc., San Diego, CA 92121-1745 at 10:00 a.m. Pacific Time, five business days after the Special Meeting called to approve the Transaction (as defined in the Voting Agreement), or at such other time and
place mutually agreed upon by the Parties, or if any of the conditions set forth in Section 7 (other than conditions with respect to actions the respective Parties will take at the Closing itself) have not been satisfied, a later date selected by
the Investors, which date shall be within five (5) Business Days (as defined below) following the satisfaction or waiver of all conditions to the obligations of the Parties to consummate the transactions to occur at the Closing (other than
conditions with respect to actions the respective Parties will take at the Closing itself) (such date, the “Closing Date“). “Business Day“ means any day, other than a Saturday, Sunday or a day on which banking
institutions in the State of California are authorized or obligated by law, regulation or executive order to close. At the Closing, the Company will cause its transfer agent to deliver to each of the Investors (i) a certificate registered in the
Investor’s name and in the denominations designated by such Investor prior to the Closing Date representing the Shares and (ii) the other documents and certificates to be delivered pursuant to Section 7 hereof, all against payment of the
purchase price. 
  
 3. REPRESENTATIONS AND WARRANTIES OF THE
COMPANY. The Company hereby represents and warrants to, and agrees with, the Investors that the statements in the following paragraphs of this Section 3 are true and correct: 
  
 3.1 Organization, Good Standing and Qualification. Each of the Company and its Subsidiaries (as defined below) is a
corporation, partnership or limited liability company duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has all requisite power and authority to own or lease and operate its properties
and to conduct its business as it is currently being conducted and is proposed to be conducted. Each of the Company and its Subsidiaries is duly licensed, authorized or qualified as a foreign corporation, partnership or limited liability company for
the transaction of business and is in good standing under the laws of each other jurisdiction in which its ownership, lease or operation of property or conduct of business requires such qualification, except where the failure to be so qualified
would not have a material adverse effect on the assets, liabilities, condition (financial or otherwise), results of operations, prospects or business of the Company and its Subsidiaries taken as a whole (“Material Adverse Effect“).
The Company is not in default under or in violation of any provision of its amended and restated certificate of incorporation (the “Certificate of Incorporation“) or its amended and restated bylaws (the “Bylaws“).
“Subsidiary“ means as to any Person (as defined below), any other Person of which more than 50% of the shares of the voting stock or other voting interests are owned or controlled, or the ability to select or elect more than 50% of
the directors or similar managers is held, directly or indirectly, by such first Person or one or more of its Subsidiaries or by such first Person and one or more of its Subsidiaries. “Person“ means any individual, corporation,
company, association, partnership, limited liability company, joint venture, trust, unincorporated organization or Governmental Authority (as defined below). 
  
 3.2 Authorization. The Company has all requisite power and authority to execute and deliver this Agreement and to perform its obligations
hereunder. All corporate action on the part of the Company necessary for the authorization, execution and delivery of this 
  

 3 

 Agreement, the performance of the obligations of the Company at the Closing, the performance of the obligations of the
Company under Section 9 hereof and the issuance and delivery of the Shares has been taken, and this Agreement has been duly executed and delivered by the Company and constitutes a valid and legally binding obligation of the Company, enforceable in
accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors’ rights generally; (ii) the effect of rules
of law governing the availability of equitable remedies; and (iii) the unenforceability under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a
liability where such indemnification or contribution is contrary to public policy or prohibited by law. 
  
 3.3 Valid Issuance of the Shares. The Shares will, as of the Closing Date, have been duly and validly authorized, reserved for issuance and, when
issued, sold and delivered by the Company in accordance with the terms of this Agreement for the consideration provided for herein, will have been duly and validly issued, will be fully paid and nonassessable and will be free of any mortgage,
pledge, lien, security interest, claim, voting agreement, conditional sale agreement, title retention agreement, restriction, option or encumbrance of any kind, character or description whatsoever (“Lien“) (other than those that may
be created by the Investors) and free of any restrictions on transfer other than restrictions on transfer under applicable federal and state securities laws and, assuming the truth and correctness of the Investors’ representations and
warranties in Section 4 below, will be issued in compliance with all applicable federal and state securities laws. 
  
 3.4 Capitalization. 
  
 (a) The entire authorized capital stock of the Company consists of 20,000,000 shares of Common Stock, of which 7,339,810 shares (not including 435,845
shares held by the Company as treasury shares) were issued and outstanding as of September 20, 2004, and 2,000,000 shares of preferred stock, par value $.0001 per share, of which 20,000 shares of the Company’s 8% Series A Cumulative Convertible
Redeemable Preferred Stock, par value $.0001 per share, and 22,000 shares of the Company’s Series B Preferred Stock are issued and outstanding as of the date of this Agreement. Except as set forth in the SEC Documents (as defined below), there
are no outstanding or authorized warrants, options, purchase rights, subscription rights, conversion rights, exchange rights or other contracts, commitments or obligations that could require the Company or any of its Subsidiaries to issue, grant,
deliver or sell or otherwise cause to be issued, granted, delivered or sold or become outstanding any capital stock of the Company or any of its Subsidiaries, except for those granted in the ordinary course of business since the dates of the SEC
Documents. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or similar rights with respect to the Company or any of its Subsidiaries. To the Company’s knowledge, there are no voting trusts, proxies
or other agreements or understandings with respect to the voting of the capital stock of the Company with the exception of the Voting Agreement. 
  
 (b) Except as set forth on Schedule 3.4(b) hereto, the registration of the Shares pursuant to Section 9 hereof will not give rise to any registration
rights on behalf of any Person under any agreement or instrument applicable to the Company. Except as set forth 
  

 4 

 on Schedule 3.4(b) hereto, other than pursuant to Section 9 hereof, no Person has any right to require the Company to
register securities of the Company under the Securities Act of 1933, as amended (the “1933 Act”). 
  
 3.5 Noncontravention. 
  
 (a) Neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby, will (i) violate any
constitution, statute, regulation, rule, ordinance, code, injunction, judgment, order, decree, ruling, charge, writ, determination or other restriction (“Law“) of any government or political subdivision or department thereof, any
governmental regulatory body, commission, board, agency or instrumentality, or any court or arbitrator or alternative dispute resolution body, in each case whether federal, state, local or foreign (“Governmental Authority“) to which
the Company or any of its Subsidiaries is subject or any provision of the Certificate of Incorporation or the Bylaws or the certificate of incorporation or bylaws or similar constituent documents of the Company’s Subsidiaries or (ii) conflict
with, result in a breach or violation of, constitute a default (with or without notice or the passage of time) under, result in the acceleration of, create in any party the right to accelerate, terminate, modify or cancel, or give rise to a right to
put or to compel a tender offer for outstanding securities of the Company or any of its Subsidiaries or require any notice, consent, waiver or approval under any agreement, contract, lease, license, loan, debt instrument, note, bond, indenture,
mortgage, deed of trust, joint venture agreement, approval of a Governmental Authority or other arrangement to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of the
Company’s or its Subsidiaries’ assets is subject (or result in the imposition of any mortgage, pledge, Lien, encumbrance, charge or other security interest upon any of such assets or properties), except in either case, where such
violation, conflict or default would not have a Material Adverse Effect. 
  
 (b) Except for (i) the filing of a Form D with the Securities and Exchange Commission (the “SEC”), (ii) filings which may be required under state securities laws and (iii) for filings under the
Hart-Scott-Rodino Antitrust Act of 1976, for which filings the Company shall be responsible, neither the Company nor any of its Subsidiaries is required to give any notice to, make any filing or registration with, or obtain any authorization,
consent or approval of any Governmental Authority in connection with the execution, delivery and performance by the Company of this Agreement and the transactions contemplated hereby. 
  
 (c) No consent or approval of the Company’s stockholders is required by Law, the Certificate of Incorporation, the
Bylaws, the rules and regulations of the Nasdaq Stock Market, or otherwise, for the execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby except as provided for in Section
8.5. 
  
 3.6 Absence of Certain Changes. Except as
disclosed in the reports required to be filed by the Company under the 1934 Act in the preceding twelve (12) months (the “SEC Documents“) or otherwise disclosed in public announcements or press releases, since August 31, 2003, the
Company and its Subsidiaries have conducted their consolidated business in the ordinary and usual course and there has been no change to the business, properties, assets, 
  

 5 

 operations, prospects, results of operations or condition (financial or otherwise) of the Company or its Subsidiaries
(taken as a whole), except for such changes which could not be reasonably expected to have a Material Adverse Effect. 
  
 3.7 No General Solicitation. Neither the Company, nor any of its Affiliates (as defined below), nor any person acting on its or their behalf, has
engaged in any form of general solicitation or general advertising (within the meaning of Regulation D (“Regulation D“) promulgated under the 1933 Act) in connection with the offer or sale of the Shares. “Affiliate“
has the meaning set forth in Rule 12b-2 promulgated under the Securities Exchange Act of 1934, as amended (the “1934 Act“), as in effect on the date hereof. The term “Affiliated“ has a correlative meaning.

  
 3.8 Disclosure. No information that has been provided
to the Investors by the Company or any of its representatives in connection with the transactions contemplated by this Agreement, and no exhibit, document, statement, certificate or schedule furnished or to be furnished to the Investors pursuant to
this Agreement, contains or will contain, as the case may be, any untrue statement of a material fact, or omits or will omit, as the case may be, to state a material fact necessary to make the statements or facts contained therein not misleading.

  
 4. REPRESENTATIONS AND WARRANTIES OF THE
INVESTORS. Each of the Investors severally and not jointly represents and warrants to the Company that the statements in the following paragraphs of this Section 4 are true and correct with respect to such Investor: 
  
 4.1 Organization and Qualification. The Investor is duly organized,
validly existing and in good standing under the laws of the jurisdiction of its organization. The Investor has all requisite power and authority to enter into and perform this Agreement and to carry out the transactions contemplated by this
Agreement. 
  
 4.2 Authorization. All action on the part of
the Investor necessary for the authorization, execution and delivery of this Agreement and the performance of all obligations of the Investor hereunder has been taken, and this Agreement has been duly executed and delivered by the Investor and
constitutes a valid and legally binding obligation of the Investor, enforceable in accordance with its terms, except as may be limited by (a) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or
affecting the enforcement of creditors’ rights generally; (b) the effect of rules of law governing the availability of equitable remedies; and (c) the unenforceability under certain circumstances under law or court decisions of provisions
providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is contrary to public policy or prohibited by law. 
  
 4.3 Purchase for Own Account. Except as permitted pursuant to Section 11.3 hereof, the Shares to be acquired by the
Investor hereunder will be acquired for investment for the Investor’s own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within the meaning of the 1933 Act, and the Investor has no present
intention of selling or otherwise distributing the same. The Investor does not have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to
the Shares. The Investor also represents that it has not been formed for the specific purpose of acquiring the Shares. 
  

 6 

 4.4 Accredited Investor Status. The Investor is an “accredited investor” within the
meaning of Regulation D. By reason of its business and financial experience, sophistication and knowledge, the Investor is capable of evaluating the risks and merits of the investment made pursuant to this Agreement. The Investor confirms that it is
able (a) to bear the economic risk of this investment, as well as other risk factors as more fully set forth herein and in the SEC Documents, (b) to hold the Shares for an indefinite period of time and (c) to bear a complete loss of the
Investor’s investment; and the Investor represents that it has sufficient liquid assets so that the illiquidity associated with this investment will not cause any undue financial difficulties or affect the Investor’s ability to provide for
its current needs and possible financial contingencies. 
  
 4.5
Restricted Securities. The Investor understands that the Shares are characterized as “restricted securities” under the 1933 Act inasmuch as they are being acquired from the Company in a transaction not involving a public offering
and that under the 1933 Act and applicable regulations thereunder such securities may be resold without registration under the 1933 Act only in certain limited circumstances. In this connection, the Investor represents that it is familiar with Rule
144 promulgated under the 1933 Act (“Rule 144“), as presently in effect, and understands the resale limitations imposed thereby and by the 1933 Act. The Investor understands that the Company is under no obligation to register any of
the securities sold hereunder except as provided in Section 9 hereof. 
  
 4.6 Due Diligence and No Solicitation. The Investor has had a reasonable opportunity to ask questions of and receive answers from the Company and its officers, and all such questions have been answered to the full satisfaction of the
Investor. At no time was the Investor presented with or solicited by any leaflet, public promotional meeting, circular, newspaper or magazine article, radio or television advertisement or any other form of general advertising. 
  
 4.7 Further Limitations on Disposition. Without in any way limiting
the representations set forth above, the Investor further agrees not to make any disposition of all or any portion of the Shares unless and until: 
  
 (a) there is then in effect a registration statement under the 1933 Act covering such proposed disposition and such disposition is made in accordance
with such registration statement; or 
  
 (b) (i) the Investor
shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of the circumstances surrounding the proposed disposition, and (ii) the Investor shall have furnished the Company at the
Investor’s expense an opinion of counsel, reasonably satisfactory to the Company that such disposition will not require registration of such securities under the 1933 Act; provided that the Company shall not require an opinion of counsel
for routine sales of shares pursuant to Rule 144. 
  

 7 

 4.8 Legends. It is understood that the certificates evidencing the Shares will bear the legends
set forth below: 
  
 (a) THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAWS. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS
PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. 
  
 (b) The legend referred to in Section 4.8(a) above shall be removed from a certificate representing such Shares if the securities represented thereby are
sold pursuant to an effective registration statement under the 1933 Act, or there is delivered to the Company such satisfactory evidence, which may include an opinion of independent counsel, as reasonably may be requested by the Company, to confirm
that neither such legend nor the restrictions on transfer set forth therein are required to ensure that transfers of such securities will not violate the registration requirements of the 1933 Act. 
  
 5. PRE-CLOSING COVENANTS OF THE PARTIES. The Parties agree as
follows with respect to the period between the execution of this Agreement and the Closing: 
  
 5.1 General. Each of the Parties will use its reasonable best efforts to take all action and to do all things necessary, proper or advisable in order to consummate and make effective the transactions
contemplated by this Agreement (including satisfaction, but not waiver, of the closing conditions set forth in Sections 7 and 8 below). 
  
 5.2 Notice of Developments. Each Party will give prompt written notice to the other of any material adverse development causing a breach of any of
its own representations and warranties in Section 3 or 4 above. No disclosure by any Party pursuant to this Section 5.2, however, shall be deemed to cure any misrepresentation, breach of warranty or breach of covenant. 
  
 5.3 Transfer of Series B Preferred Stock. Each of the Investors,
severally and not jointly, agrees with, and covenants to, the Company that such Investor shall not, except as contemplated by the terms of this Agreement, sell, transfer, pledge, assign or otherwise dispose of, or enter into any contract, option or
other arrangement (including any profit-sharing arrangement) or understanding with respect to the sale, transfer, pledge, assignment or other disposition of, any shares of Series B Preferred Stock to any person (any such action, a
“Transfer”). For purposes of clarification, the term “Transfer” shall include, without limitation, any short sale (including any “short sale against the box”), pledge, transfer, and the establishment of any open
“put equivalent position” within the meaning of Rule 16a-1(h) under the 1934 Act. Notwithstanding the foregoing, Transfers of shares of Series B Preferred Stock as bona fide gifts to a transferee reasonably acceptable to the Company shall
not be prohibited by this Agreement; provided that in the case of any such transfer, each transferee shall execute and deliver to the Company a valid and binding counterpart to this Agreement and agree to be bound by all the obligations of the
Investors hereunder. 
  

 8 

 6. POST-CLOSING COVENANTS OF THE PARTIES. 
  
 6.1 Listing. So long as the Investors or their respective Affiliates
Beneficially Own any Shares, the Company shall use its best efforts to ensure that the shares of Common Stock continue to be quoted on the Nasdaq Stock Market; provided, however, this Section 6.1 shall not restrict the Company from
engaging in any reclassification, capital reorganization or other change in the outstanding shares of Common Stock or any consolidation or merger of the Company with or into another corporation or any other transaction in which the stockholders of
the Company are required to exchange their shares of Common Stock for stock or other securities of the Company or any other Person. “Beneficially Own“ with respect to any securities means having “beneficial ownership” of
such securities (as determined pursuant to Rule 13d-3 promulgated under the 1934 Act as in effect on the date hereof, except that a Person shall be deemed to Beneficially Own all such securities that such Person has the right to acquire by
conversion, exercise of option or otherwise whether such right is exercisable immediately or after the passage of time). The terms “Beneficial Ownership“ and “Beneficial Owner“ have correlative meanings. 

 
 7. CONDITIONS TO THE INVESTORS’ OBLIGATIONS AT CLOSING.

  
 The obligations of the Investors under Section 2 of this
Agreement with respect to the Closing are subject to the fulfillment or waiver, on the Closing Date, of each of the following conditions: 
  
 7.1 Representations and Warranties True. The representations and warranties of the Company contained in Section 3 qualified as to materiality shall
be true and correct in all respects, and those not so qualified shall be true and correct in all material respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of the
Closing Date (except where such representation and warranty speaks by its terms as of a different date, in which case it shall be true and correct as of such date). The Company shall have delivered to the Investors at the Closing a certificate in
form and substance reasonably satisfactory to the Investors dated the Closing Date and signed by the Chief Executive Officer or an Executive Vice President and the Chief Financial Officer or Senior Vice President of Accounting of the Company to the
effect that the condition set forth in this Section 7.1 has been satisfied. 
  
 7.2 Compliance with Covenants. The Company shall have performed all of its obligations hereunder in all material respects and complied with all agreements, undertakings, covenants and conditions required
hereunder to be performed by it at or prior to the Closing. The Company shall have delivered to the Investors at the Closing a certificate in form and substance reasonably satisfactory to the Investors dated the Closing Date and signed by the Chief
Executive Officer or an Executive Vice President and the Chief Financial Officer or Senior Vice President of Accounting of the Company to the effect that the condition set forth in this Section 7.2 has been satisfied. 
  
 7.3 No Litigation. 
  
 (a) No Law shall have been promulgated, enacted or entered that restrains,
enjoins, prevents, materially delays, prohibits or otherwise makes illegal the performance of this Agreement or the transactions contemplated hereby. 
  
 (b) No action, suit or proceeding shall be pending or threatened before any Governmental Authority wherein an unfavorable injunction, judgment, order,
decree, ruling 
  

 9 

 or charge would (i) prevent, materially delay, prohibit or otherwise make illegal the consummation of any of the
transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded following consummation (and no such injunction, judgment, order, decree, ruling or charge shall be in effect) or (iii)
affect adversely the right of the Investors to own the Shares. 
  
 7.4 Securities Exemptions. The offer and sale of the Shares to the Investors pursuant to this Agreement shall be exempt from the registration requirements of the 1933 Act, the qualification requirements of the California Corporate
Securities Law of 1968 (the “California Securities Law“) and the registration and/or qualification requirements of all other applicable state securities laws. 
  
 7.5 Proceedings. All corporate and other proceedings to be taken by the Company in connection with this Agreement and
with respect to the transactions contemplated hereby to be completed at or prior to the Closing and documents incident thereto shall have been completed in form and substance reasonably satisfactory to the Investors, and the Investors shall have
received all such counterpart originals or certified or other copies of this Agreements and such other documents as it may reasonably request. 
  
 7.6 No Material Adverse Effect. No event shall have occurred and no condition shall have arisen or been created since the date of this Agreement
which has had, or would be reasonably likely to have, a Material Adverse Effect. 
  
 8. CONDITIONS TO THE COMPANY’S OBLIGATIONS AT CLOSING. The obligations of the Company to the Investors under this Agreement with respect to the Closing are subject to the fulfillment or
waiver on the Closing Date of each of the following conditions: 
  
 8.1 Representations and Warranties True. The representations and warranties of the Investors contained in Section 4 qualified as to materiality shall have been true and correct in all respects, and those not so qualified shall have
been true and correct in all material respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of the Closing Date (except where such representation and warranty speaks by its
terms as of a different date, in which case it shall be true and correct as of such date). 
  
 8.2 Evidence of Cancellation. The Investors shall have: (i) delivered to the Company for cancellation the promissory note issued by the Company pursuant to the Bridge Loan, (ii) tendered to the Company the
certificates representing all 22,000 outstanding shares of the Company’s Series B Preferred Stock, and (iii) delivered to the Company such evidence or documentation as reasonably requested by the Company evidencing termination of all
obligations of the Company under Vendor Financing Agreement, including any liens, security interests or encumbrances of any kind created under such agreement, and the Deposit Agreement. 
  

 10 

 8.3 No Litigation. 
  
 (a) No Law shall have been promulgated, enacted or entered that restrains, enjoins, prevents, materially delays, prohibits
or otherwise makes illegal the performance of this Agreement or the transactions contemplated hereby. 
  
 (b) No action, suit or proceeding shall be pending or threatened before any Governmental Authority wherein an unfavorable injunction, judgment, order,
decree, ruling or charge would (i) prevent, delay, prohibit or otherwise make illegal the consummation of any of the transactions contemplated by this Agreement, or (ii) cause any of the transactions contemplated by this Agreement to be rescinded
following consummation (and no such injunction, judgment, order, decree, ruling or charge shall be in effect). 
  
 8.4 Securities Exemptions. The offer and sale of the Shares to the Investors pursuant to this Agreement shall be exempt from the registration
requirements of the 1933 Act, the qualification requirements of the California Securities Law and the registration and/or qualification requirements of all other applicable state securities laws. 
  
 8.5 Stockholder Approval. Each element of the Transaction shall have
been approved by the required vote of the stockholders of the Company as required by continued listing requirements of the Nasdaq Stock Market and the Delaware General Corporation Law. 
  
 8.6 Termination of Security Interest. The Price Group shall have executed, filed or recorded any and all such
statements, notices and agreements, taken such action and obtained such certificates and documents in accordance with all applicable laws, statutes and regulations as may be necessary or advisable to terminate any liens, security interests, pledges
or any other encumbrances created under the Vendor Financing Agreement. 
  
 9. REGISTRATION STATEMENT FOR RESALE OF THE SHARES. 
  
 9.1 Registration. As promptly as practicable after the Closing but in any event within ninety (90) days following the Closing Date, the Company shall prepare and file with the SEC a registration statement (the
“Registration Statement“), and maintain effective for the period specified in Section 9.2(a) for use by the Investors and their respective Affiliates at any time during such period with respect to the offering and sale or other
disposition of the Shares. 
  
 9.2 Company Obligations. In
the case of each registration effected by the Company pursuant to this Section 9, the Company will keep the Investors, as applicable, advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the
Company will: 
  
 (a) use its best efforts to cause such
registration to remain effective at all times until the earlier of (i) such time as the distribution described in the registration statement relating to the Shares has been completed and (ii) two (2) years from the Closing Date; 
  
 (b) prepare and file with the SEC such amendments and post-effective
amendments to such registration statement and supplements to the prospectus as may be (i) reasonably requested by the holders of a majority of the Shares, (ii) reasonably requested by any participating holder (to the extent such request relates to
information relating to such holder), or (iii) necessary to keep such registration effective for the period of time required by this Section 9; 
  

 11 

 (c) prepare and deliver to the Investors as many copies of each preliminary and final prospectus and
other documents incident thereto as each of the Investors from time to time may reasonably request; 
  
 (d) immediately notify the Investors, at any time when a prospectus relating to a registration of Shares is required to be delivered under the 1933 Act,
of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, and, at the request of the Investors, prepare a supplement or amendment to such registration statement so that, as thereafter delivered to the purchasers of such Shares, such prospectus will
not contain any untrue statement of a material fact or omit to state a material fact required to be stated or necessary to make the statements therein not misleading; 
  
 (e) use its best efforts to register or qualify and maintain the qualification of the Shares covered by such registration
under such state securities or “blue sky” laws for offers and sales to the public as the Investors shall reasonably request; provided, however, that the Company shall not be obligated to qualify as a foreign corporation to do
business under the laws of or become subject to taxation in, any jurisdiction in which it shall not be then qualified, or to file any general consent to service of process; 
  
 (f) otherwise use its best efforts to comply with the securities laws of the United States and other applicable
jurisdictions and all applicable rules and regulations of the SEC and comparable Governmental Authorities in other applicable jurisdictions; 
  
 (g) notify the Investors (i) when the Registration Statement or any amendment thereto has been filed or becomes effective, when the prospectus or any
amendment or supplement thereto has been filed and to furnish the Investors with copies thereof, (ii) of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or any order preventing or suspending the
use of the preliminary prospectus or the Final Prospectus (as defined below) or the initiation or threatening of any proceedings for such purposes, and (iii) the receipt by the Company of any notification with respect to the suspending of the
qualification of the Shares for offering or sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and 
  
 (h) with a view to making available the benefits of certain rules and regulations of the SEC which may permit the sale of restricted securities to the
public without registration, the Company agrees to: (i) make and keep public information available as those terms are understood and defined in Rule 144; (ii) use its best efforts to file with the SEC in a timely manner all reports and other
documents required of the Company under the 1933 Act and the 1934 Act at any time after it has become subject to such reporting requirements; and (iii) so long as an Investor or transferee of an Investor owns any Shares, furnish to such Investor or
transferee of such Investor upon request, a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of the 1933 Act and the 1934 Act, a 
  

 12 

 copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as such
Investor or transferee of such Investor may reasonably request in availing itself of any rule or regulation of the SEC allowing such Investor or transferee of such Investor to sell any such securities without registration. 
  
 9.3 Restrictions on Registrations. If at any time or from time to time
after the effective date of the Registration Statement, the Company promptly notifies the Investors in writing of the existence of a Potential Material Event (as defined below), the Investors shall not offer or sell any Shares or engage in any other
transaction involving or relating to the Shares, from the time of the giving of notice with respect to a Potential Material Event until the Investors receive written notice from the Company that such Potential Material Event either has been
disclosed to the public or no longer constitutes a Potential Material Event. If a Potential Material Event shall occur prior to the date the Registration Statement is filed, then notwithstanding Section 9.1 above, the Company’s obligation to
file the Registration Statement shall be delayed until such Potential Material Event either has been disclosed to the public or no longer constitutes a Potential Material Event. “Potential Material Event“ means any of the following:
(a) the possession by the Company of material information not ripe for disclosure in a registration statement, as determined in good faith by the Chief Executive Officer or the Board of Directors that disclosure of such information in a Registration
Statement would be materially detrimental to the business and affairs of the Company; or (b) any material engagement or activity by the Company which would, in the good faith determination of the Chief Executive Officer or the Board of Directors, be
materially adversely affected by disclosure in a registration statement at such time, which determination shall be accompanied by a good faith determination by the Chief Executive Officer or the Board of Directors that the applicable Registration
Statement would be materially misleading absent the inclusion of such information. In no event shall the suspension of the Registration Statement (or the permissible delay in filing a Registration Statement) (i) exceed ninety (90) days on any one
occasion as a result of a Potential Material Event or (ii) be permitted more than once during any 12-month period. 
  
 9.4 Investor Obligations and Rights. 
  
 (a) Each of the Investors shall cooperate as reasonably requested by the Company with the Company in connection with the preparation of the Registration
Statement, and for so long as the Company is obligated to file and keep effective the Registration Statement, shall provide to the Company, in writing, for use in the Registration Statement, all such information regarding such Investor and its plan
of distribution of the Shares as may be reasonably necessary to enable the Company to prepare the Registration Statement and prospectus covering the Shares, to maintain the currency and effectiveness thereof and otherwise to comply with all
applicable requirements of law in connection therewith. Each of the Investors shall have the right to prepare any portions of the Registration Statement requiring information regarding such Investor and its plan of distribution of the Shares.

  
 (b) During such time as an Investor may be engaged in a
distribution of the Shares, such Investor shall comply with Regulation M promulgated under the 1934 Act and pursuant thereto it shall, among other things, (i) not engage in any stabilization activity in connection with the securities of the Company
in contravention of such regulation; (ii) distribute the Shares under the Registration Statement solely in the manner described in the Registration 
  

 13 

 Statement; and (iii) cease distribution of such Shares pursuant to such Registration Statement upon receipt of written
notice from the Company that the prospectus covering the Shares contains any untrue statement of a material fact or omits a material fact required to be stated therein or necessary to make the statements therein not misleading. 
  
 (c) Each of the Investors hereby covenants with the Company not to make any
sale of the Shares without effectively causing the prospectus delivery requirements under the 1933 Act to be satisfied unless the sale is made pursuant to an exemption from registration. 
  
 (d) Each of the Investors acknowledges and agrees that the Shares sold pursuant to the Registration Statement are not
transferable on the books of the Company unless the stock certificate submitted to the transfer agent evidencing the Shares is accompanied by a certificate reasonably satisfactory to the Company to the effect that (i) the Shares have been sold in
accordance with this Agreement and the Registration Statement and (ii) the requirement of delivering a current prospectus has been satisfied. 
  
 (e) Following termination of the effectiveness of the Registration Statement, each of the Investors shall discontinue sales of Shares pursuant thereto
upon receipt of notice from the Company of its intention to remove from registration the Shares covered thereby which remain unsold, and each of the Investors shall promptly notify the Company of the number of Shares registered that remain unsold
immediately upon receipt of the notice from the Company. 
  
 (f)
Each of the Investors will observe and comply with the 1933 Act, the 1934 Act and the general rules and regulations thereunder, as now in effect and as from time to time amended and including those hereafter enacted or promulgated, in connection
with any offer, sale, pledge, transfer or other disposition of the Shares or any part thereof. 
  
 9.5 Indemnification. 
  
 (a) The Company will indemnify and hold harmless to the fullest extent permitted by law each of the Investors, as applicable, each of its Affiliates and each of their respective officers, directors, shareholders, employees, advisors, agents
and partners, and each person controlling each of the Investors, with respect to each registration which has been effected pursuant to this Section 9 against all Losses (as defined below) jointly and severally arising out of or based on any untrue
statement (or alleged untrue statement) of a material fact contained in any prospectus, offering circular or other document (including any amendment or supplement thereto or any documents incorporated by reference therein and any related
registration statement, notification or the like) incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, or any violation by the Company of the 1933 Act or the 1934 Act or any rule or regulation thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any such
registration, qualification or compliance, and will reimburse each of the Investors, each of its Affiliates and each of their respective officers, directors, shareholders, employees, advisors, agents and partners, and each person controlling each of
the Investors for 
  

 14 

 any legal and any other expenses reasonably incurred in connection with investigating and defending any such Losses;
provided, however, that the Company will not be liable in any such case to the extent that any such Losses arise out of or is based on any untrue statement or omission based upon written information furnished to the Company by the
Investors and stated expressly to be specifically for use therein. “Losses“ shall mean, collectively, any and all losses, penalties, judgments, suits, costs, claims, liabilities, damages and expenses (including, without limitation,
reasonable attorneys’ fees and disbursements). 
  
 (b) Each
of the Investors will, if Shares held by it are included in the securities as to which such registration, qualification or compliance is being effected, indemnify and hold harmless to the fullest extent permitted by law the Company, each of its
Affiliates and their respective directors, employees, advisors, agents and officers and each person who controls the Company, against all Losses arising out of or based on any untrue statement (or alleged untrue statement) of a material fact
contained in any such registration statement, prospectus, offering circular or other document made by such Investor in writing, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make
the statements by such Investor therein not misleading, and will reimburse the Company and its directors, officers, partners, persons, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or
defending any such Losses, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other
document in reliance upon and in conformity with written information furnished to the Company by such Investor and stated expressly to be specifically for use therein; provided, however, that the obligations of each of the Investors
hereunder shall be limited to an amount equal to the net proceeds to such Investor of securities sold as contemplated herein. 
  
 (c) Each party entitled to indemnification under this Section 9.5 (the “Indemnified Party“) shall give notice to the party required to
provide indemnification (the “Indemnifying Party“) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought and shall permit the Indemnifying Party to assume the defense of any such
claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall
not unreasonably be withheld) and the Indemnified Party may participate in such defense at such party’s expense (unless (i) the Indemnifying Party has agreed in writing to pay such fees or expenses, (ii) the Indemnifying Party shall have failed
to assume the defense of such claim within a reasonable time after receipt of notice of such claim from the Person entitled to indemnification hereunder and employ counsel reasonably satisfactory to such Person, (iii) the Indemnified Party has
reasonably concluded (based on the written advice of counsel) that there may be legal defenses available to it or other Indemnified Parties that are different from or in addition to those available to the Indemnifying Party, or (iv) the Indemnified
Party shall have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the Indemnified Party in such action, in which case the fees and expenses of counsel shall be at the expense of the Indemnifying
Party), and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 9 unless the Indemnifying Party is materially
prejudiced thereby. If such defense is not assumed by the Indemnifying Party, the Indemnifying Party will not be subject to any liability for any 
  

 15 

 settlement made without its consent, but such consent may not be unreasonably withheld. If the Indemnifying Party assumes
the defense, the Indemnifying Party shall not have the right to settle such action without the written consent of the Indemnified Party. No Indemnifying Party, in the defense of any such claim or litigation shall, except with the consent of each
Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to
such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with the defense
of such claim and litigation resulting therefrom. 
  
 If the
indemnification provided for in this Section 9.5 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any Losses referred to herein, then the Indemnifying Party, in lieu of indemnifying such
Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the
Indemnified Party on the other in connection with the statements or omissions which resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and
of the Indemnified Party shall be determined by reference to, among other things, whether the untrue (or alleged untrue) statement of a material fact or the omission (or alleged omission) to state a material fact relates to information supplied by
the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. Notwithstanding anything in this Section 9.5 to the
contrary, no Indemnifying Party (other than the Company) shall be required pursuant to this Section 9.5 to contribute any amount in excess of the amount by which the net proceeds received by such Indemnifying Party from the sale of Shares in the
offering to which the Losses of the Indemnified Party relates exceeds the amount of any damages which such Indemnifying Party has otherwise been required to pay by reason of such untrue statement or omission. 
  
 The parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 9.5 were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in the immediately preceding paragraph. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
  
 (d) The foregoing indemnity agreement of the Company and Investors is
subject to the condition that, insofar as they relate to any Losses made in a preliminary prospectus but eliminated or remedied in the amended prospectus on file with the SEC at the time the registration statement in question becomes effective or
the amended prospectus filed with the SEC pursuant to Rule 424(b) promulgated under the 1933 Act (the “Final Prospectus“), such indemnity or contribution agreement shall not inure to the benefit of an Investor if a copy of the Final
Prospectus was timely furnished to such Investor in sufficient quantities for delivery and was not furnished to the person asserting the loss, liability, claim or damage at or prior to the time such action is required by the 1933 Act. 
  

 16 

 (e) Notwithstanding any other provision of this Agreement, the obligations of the parties under this
Section 9.5 shall survive indefinitely. 
  
 9.6 Expenses.
The Company shall pay all expenses incident to the registration of the Shares under this Section 9 including without limitation, all registration and filing fees, all fees and expenses of complying with securities or blue sky laws, all word
processing, duplicating and printing expenses, and the fees and disbursements of counsel for the Company and its independent public accountants. With respect to sales of the Shares, the Investors shall pay all underwriting discounts and commissions
and fees of underwriters, selling brokers, dealer managers or similar securities industry professionals relating to the distribution of the Shares to be sold by the Investors, the fees and disbursements of counsel retained by the Investors and
transfer taxes, if any. 
  
 10. TERMINATION.

  
 10.1 Termination. This Agreement may be terminated at
any time prior to the Closing: 
  
 (a) by mutual written
agreement of the Company and the Investors; 
  
 (b) by either the
Investors or the Company (provided that the terminating Party is not then in material breach of any representation, warranty, covenant or other agreement contained in this Agreement) if the Closing shall not have been consummated on or before
December 31, 2004; 
  
 (c) by either the Investors or the Company
if a court of competent jurisdiction or a Governmental Authority shall have issued a non-appealable final judgment, injunction, order, ruling or decree or taken any other action having the effect of permanently restraining, enjoining or otherwise
prohibiting the transactions contemplated by this Agreement; provided that the Party seeking to terminate this Agreement pursuant to this clause (c) shall have used its reasonable best efforts to have such judgment, injunction, order, ruling
or decree lifted, vacated or denied; or 
  
 (d) by either the
Investors or the Company (provided that the terminating Party is not then in material breach of any representation, warranty, covenant or other agreement contained in this Agreement) in the event of a material breach by the other Party of any
representation or warranty contained in this Agreement which cannot be or has not been cured within thirty (30) days after the giving of written notice to the breaching Party of such breach. 
  
 10.2 Effect of Termination. In the event of the termination of this
Agreement pursuant to Section 10.1, this Agreement shall forthwith become void and there shall be no liability on the part of any Party hereto (or any stockholder, director, officer, partner, employee, agent, consultant or representative of such
Party) except as set forth in this Section 10.2, provided that nothing contained in this Agreement shall relieve any party from liability for any breach of this Agreement and provided further that Section 11 shall survive
termination of this Agreement. 
  

 17 

 11. MISCELLANEOUS. 
  
 11.1 Survival of Warranties. The representations and warranties of the Company and the Investors contained in or made
pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing for a period of twenty-four (24) months from the Closing Date and shall in no way be affected by any knowledge or investigation of the subject
matter thereof made by or on behalf of the Investors or the Company, as the case may be. 
  
 11.2 Specific Performance. The parties hereto specifically acknowledge that monetary damages are not an adequate remedy for violations of this Agreement, and that any party hereto may, in its sole discretion,
apply to a court of competent jurisdiction for specific performance or injunctive or such other relief as such court may deem just and proper in order to enforce this Agreement or prevent any violation hereof and, to the extent permitted by
applicable Law and to the extent the party seeking such relief would be entitled on the merits to obtain such relief, each party waives any objection to the imposition of such relief. 
  
 11.3 Successors and Assigns. 
  
 (a) This Agreement shall bind and inure to the benefit of the Company and the Investors and their respective successors,
permitted assigns, heirs and personal representatives; provided that the Company may not assign its rights or obligations under this Agreement to any Person without the prior written consent of the Investors.  
  
 (b) Notwithstanding Section 11.3(a) or any other provision to the contrary
in this Agreement, the Investors may assign any and all of their rights and obligations under Section 9 hereof in connection with the transfer to such assignee of at least 1,000 Shares. 
  
 11.4 Governing Law. 
  
 (a) This Agreement shall be governed by and construed under the internal laws of the State of California as applied to agreements among California
residents entered into and to be performed entirely within that State, without reference to principles of conflict of laws or choice of law thereof. 
  
 (b) The Parties hereto hereby agree that the appropriate and exclusive forum for any disputes arising out of this Agreement solely between the Company
and any of the Investors shall be the United States District Court for the Southern District of California, and, if such court will not hear any such suit, the courts of the state of Delaware, and the parties hereto hereby irrevocably consent to the
exclusive jurisdiction of such courts, and agree to comply with all requirements necessary to give such courts jurisdiction. The Parties hereto further agree that the Parties will not bring suit with respect to any disputes arising out of this
Agreement except as expressly set forth below for the execution or enforcement of judgment, in any jurisdiction other than the above specified courts. Each of the Parties hereto irrevocably consents to the service of process in any action or
proceeding hereunder by the mailing of copies thereof by registered or certified airmail, postage prepaid, to the address specified in Section 11.7 hereof. The foregoing shall not limit the rights of any party hereto to serve process in any other
manner permitted by the law or to obtain execution of judgment in any other jurisdiction. The Parties further agree, to 
  

 18 

 the extent permitted by law, that final and unappealable judgment against any of them in any action or proceeding
contemplated above shall be conclusive and may be enforced in any other jurisdiction within or outside the United States by suit on the judgment, a certified or exemplified copy of which shall be conclusive evidence of the fact and the amount of
indebtedness. 
  
 11.5 Counterparts. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 11.6 Headings. The headings and captions used in this Agreement are used for convenience only and are not to be considered in construing or
interpreting this Agreement. All references in this Agreement to sections, paragraphs, exhibits and schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits and schedules attached hereto, all of which exhibits
and schedules are incorporated herein by this reference. 
  
 11.7
Notices. All notices, requests, demands, claims and other communications hereunder will be in writing. Any notice, request, demand, claim or other communication hereunder shall be deemed duly given if (and then four (4) Business Days after)
it is sent by registered or certified mail, return receipt requested, postage prepaid and addressed to the intended recipient as set forth below: 
  

			
	To the Company:	 	PriceSmart, Inc.
	 	 	9740 Scranton Road
	 	 	San Diego, CA 92121-1745
	 	 	Attention: Robert M. Gans, Esq.
	 	 	Telephone: (858) 404-8821
	 	 	Facsimile: (858) 404-8828
		
	with a copy to:	 	Latham & Watkins LLP
	 	 	12636 High Bluff Drive, Suite 300
	 	 	San Diego, CA 92130
	 	 	Attention: Robert E. Burwell, Esq.
	 	 	Telephone: (858) 523-5400
	 	 	Facsimile: (858) 523-5450
		
	To the Investors:	 	To the names and addresses set forth on the signature pages hereto

  
 Any Party may send any notice,
request, demand, claim or other communication hereunder to the intended recipient at the address set forth above using any other means (including personal delivery, expedited courier, messenger service or ordinary mail), but no such notice, request,
demand, claim or other communication shall be deemed to have been duly given unless and until it actually is received by the intended recipient. Any Party may change the address to which notices, requests, demands, claims and other communications
hereunder are to be delivered by giving the other Parties notice in the manner herein set forth. 
  

 19 

 11.8 No Finder’s Fees. Each Party represents that it neither is nor will be obligated for any
finder’s or broker’s fee or commission in connection with this transaction. The Company agrees to indemnify and hold harmless each of the Investors from any liability for any commission or compensation in the nature of a finder’s or
broker’s fee (and any asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 
  
 11.9 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Investors. 
  
 11.10 Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing
party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
  
 11.11 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law,
such provision(s) shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision(s) were so excluded and shall be enforceable in accordance with its terms. 
  
 11.12 Entire Agreement. This Agreement, together with all exhibits and
schedules hereto, constitutes the entire agreement and understanding of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence, agreements, understandings duties or obligations between the
Parties with respect to the subject matter hereof. 
  
 11.13 No
Third Party Beneficiaries. This Agreement is for the sole benefit of the Parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended or shall confer upon any other Person any legal or
equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, except that the provisions of Section 9.5 shall inure to the benefit of and be enforceable by each Indemnified Party. 
  
 11.14 Public Announcements. The Investors and the Company shall
consult with each other before issuing any press release with respect to this Agreement or the transactions contemplated hereby and neither shall issue any such press release or make any such public statement without the prior consent of the other,
which consent shall not be unreasonably withheld; provided, however, that a Party may, without the prior consent of the other Party, issue such press release or make such public statement as may upon the advice of counsel be required
by law if it has used commercially reasonable efforts to consult with the other Party prior thereto. The Parties hereby consent to the filing of this Agreement by the Company and a Schedule 13D and Form 4 by each of the Investors, as applicable,
with the SEC. 
  
 11.15 Further Assurances. From and after
the date of this Agreement, upon the request of any of the Investors or the Company, the Company and the Investors shall execute and 
  

 20 

 deliver such instruments, documents or other writings as may be reasonably necessary or desirable to confirm and carry
out and to effectuate fully the intent and purposes of this Agreement. 
  
 11.16 Fees and Expenses. Except as otherwise provided in this Agreement, each of the Parties shall each bear its own expenses incurred in connection with the negotiation and execution of this Agreement and each other agreement,
document and instrument contemplated by this Agreement and the consummation of the transactions contemplated hereby and thereby. 
  
 11.17 Waiver of Jury Trial. THE COMPANY AND THE INVESTORS HEREBY WAIVE ANY RIGHT THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION,
PROCEEDING OR LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT. 
  
 [Remainder of Page Intentionally Left Blank] 
  

 21 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

  

			
	 THE COMPANY:

	
	 PRICESMART, INC.

		
	By:	 	 /s/ Robert M. Gans

	Name:	 	Robert M. Gans
	Title:	 	Executive Vice President and General Counsel
	
	THE INVESTORS:
	
	SOL AND HELEN PRICE TRUST
		
	By:	 	 /s/ Sol Price

	Name:	 	Sol Price
	Title:	 	Trustee
		
	Address:	 	7979 Ivanhoe Avenue, #520
	 	 	La Jolla, California 92037
		
	Facsimile:	 	(858) 551-2314
	Phone:	 	(858) 551-2311
	
	ROBERT AND ALLISON PRICE TRUST 1/10/75
		
	By:	 	 /s/ Robert E. Price

	Name:	 	Robert E. Price
	Title:	 	Trustee
		
	By:	 	 /s/ Allison Price

	Name:	 	Allison Price
	Title:	 	Trustee
		
	Address:	 	7979 Ivanhoe Avenue, #520
	 	 	La Jolla, California 92037
		
	Facsimile:	 	(858) 551-2314
	Phone:	 	(858) 551-2311

  
 SIGNATURE PAGE TO THE

 STOCK PURCHASE AGREEMENT 
  

 Page 1 of 2 

			
	THE PRICE FAMILY CHARITABLE FUND
		
	By:	 	 /s/ James Cahill

	Name:	 	James Cahill
	Title:	 	Executive Vice President
		
	Address:	 	7979 Ivanhoe Avenue, #520
	 	 	La Jolla, California 92037
		
	Facsimile:	 	(858) 551-2314
	Phone:	 	(858) 551-2311
	
	ROBERT AND ALLISON PRICE CHARITABLE
	REMAINDER TRUST
		
	By:	 	 /s/ Robert E. Price

	Name:	 	Robert E. Price
	Title:	 	Trustee
		
	By:	 	 /s/ Allison Price

	Name:	 	Allison Price
	Title:	 	Trustee
		
	Address:	 	7979 Ivanhoe Avenue, #520
	 	 	La Jolla, California 92037
		
	Facsimile:	 	(858) 551-2314
	Phone:	 	(858) 551-2311
	
	THE PRICE GROUP, LLC
		
	By:	 	 /s/ James Cahill

	Name:	 	James Cahill
	Title:	 	Manager
		
	Address:	 	7979 Ivanhoe Avenue, #520
	 	 	La Jolla, California 92037
		
	Facsimile:	 	(858) 551-2314
	Phone:	 	(858) 551-2311

  
 SIGNATURE PAGE TO THE

 STOCK PURCHASE AGREEMENT 
  

 Page 2 of 2 

 SCHEDULE 3.4(b) 
  
 Registration Rights: 
  

	 	1.	Under a Registration Rights Agreement dated June 3, 2000, PSC, S.A. (“PSC”) possesses registration rights with respect to an aggregate of 679,500 shares of the
Company’s Common Stock. Pursuant to the Registration Rights Agreement, the Company filed registration statements on Form S-3 on July 27, 2000 and August 8, 2001, which were subsequently declared effective. PSC has the right to require that the
registration statement be kept effective until PSC or a permitted assignee has completed the distribution of its shares as described in the registration statements. 

  

	 	2.	Under a Series B Preferred Stock Purchase Agreement dated July 8, 2003, the Sol and Helen Price Trust, The Price Family Charitable Fund, The Price Group LLC, the Robert &
Allison Price Charitable Remainder Trust and the Robert & Allison Price Trust 1/10/75 (collectively, the “Series B Investors”) possess registration rights with respect to an aggregate of 1,100,000 shares of the Company’s Common
Stock. On August 5, 2003, the Company and the Series B Investors entered into a letter agreement extending to 180 days the period in which the Company must file a registration statement on Form S-3 with respect to the registrable shares. Once filed
and declared effective, the Series B Investors have the right to require that the registration statement be kept effective until the earlier of (1) such time as the Series B Investors have completed the distribution of their shares as described in
the registration statement and (2) two years from their purchase of the shares of Series B Preferred Stock. 

  

	 	3.	Under a Common Stock Purchase Agreement dated October 22, 2003, The Sol and Helen Price Trust and The Robert & Allison Price Trust 1/10/75 (collectively, the “Trusts”)
possesses registration rights with respect to an aggregate of 500,000 shares of the Company’s Common Stock. Once filed and declared effective, the Trusts have the right to require that the registration statement be kept effective until the
earlier of (1) such time as the distribution described in the registration statement relating to the shares has been completed and (ii) two (2) years from the purchase of the shares of Common Stock. 

  
 SCHEDULE 3.4(b) 

 EXHIBIT A 
  
 Schedule of Investors 
  
 Sol and Helen Price Trust 
  
 Robert and Allison Price Trust 1/10/75 
  
 The
Price Family Charitable Fund 
  
 The Price Group, LLC 
  
 Robert and Allison Price Charitable Remainder Trust 
 EXHIBIT A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]